

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>A61K 31/19, 31/13, A61P 25/18, 25/24, 25/28</b>		<b>A1</b>	(11) International Publication Number: <b>WO 00/66110</b> (43) International Publication Date: 9 November 2000 (09.11.00)
(21) International Application Number: PCT/EP00/03456 (22) International Filing Date: 17 April 2000 (17.04.00) (30) Priority Data: 60/131,647 29 April 1999 (29.04.99) US 99108480.7 30 April 1999 (30.04.99) EP (71) Applicant (for all designated States except US): MERCK PATENT GMBH [DE/DE]; Frankfurter Strasse 250, D-64293 Darmstadt (DE). (72) Inventors; and (75) Inventors/Applicants (for US only): ARLT, Michael [DE/DE]; Friedrich-Ebert-Strasse 73, D-64342 Seeheim (DE). BAR-TOSZYK, Gerd [DE/DE]; Kreuzstrasse 57, D-64331 Weiterstadt (DE). (74) Common Representative: MERCK PATENT GMBH; D-64271 Darmstadt (DE).			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: GLYCINE CLEAVAGE SYSTEM INHIBITORS AS POTENTIAL ANTIPSYCHOTICS			
(57) Abstract  The invention relates to inhibitors of the glycine cleavage system and their use as potential antipsychotic agents. The invention relates furthermore to a process for treating humans having psychosis, psychosis associated with an illness, schizophrenia, Alzheimer's disease or other related psychotic disorders.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## Glycine Cleavage System Inhibitors as Potential Antipsychotics

The invention relates to inhibitors of the glycine cleavage system and their use as  
5 potential antipsychotic agents. The invention relates furthermore to a process for  
treating humans having psychosis, psychosis associated with an illness,  
schizophrenia, Alzheimers disease or other related psychotic disorders.

### BACKGROUND AND TECHNICAL FIELD OF THE INVENTION

10 Glycine is a neurotransmitter in the central nervous system. There, strychnine  
sensitive glycine receptors exist, where glycine serves as an inhibitory  
neurotransmitter. In addition there is a glycine binding site located at the NMDA  
receptor. Here, glycine serves as a excitatory coagonist. For the full activation of  
the glycine receptor the presence of glutamate and glycine is mandatory.

15 NMDA Antagonists such as phencyclidine (PCP) and related drugs (e.g.  
ketamine or dizocilpine) induce symptoms in human volunteers which are not  
distinguishable from schizophrenia (Luby et al., 1959; Rosenbaum et al., 1959;  
Bakker and Amini, 1961), i.e. they induce a spectrum of symptoms including the  
positive, negative and cognitive aspects of schizophrenia (Krystal et al., 1994;  
20 Mulhotra et al., 1996). In addition, PCP provokes an exacerbation of symptoms in  
patients suffering from schizophrenia (Lathi et al., 1995; Malhotra et al., 1997).  
PCP-induced emotional, cognitive and behavioural changes represent not only a  
clinical model of schizophrenia (Luby et al., 1962), but moreover PCP-induced  
behavioural changes in mice and rats mimicking the symptoms of schizophrenia  
25 in these model organisms are now frequently used animal models for  
schizophrenia (e.g. Freed et al., 1984) and have been validated with many  
antischizophrenic drugs with different mechanisms of action (e.g. Jackson et al.,  
1993; Gleason et al., 1997; Vanover, 1997; Krebs-Thomson et al., 1998).  
Amongst these animal models utilizing mice and rats, the most prominent models  
30 are PCP-induced hyperlocomotion to model the positive and negative symptoms  
of schizophrenia and PCP-induced disruption of prepulse inhibition revealing the  
cognition deficit symptoms of schizophrenia.

*Glycine, Glycine (Partial) Agonists and Schizophrenia*

- Glycine and partial agonists at the glycine site have been evaluated in clinical trials (D'Souza 1995). In particular high doses of glycine gave very promising results (Zylberman 1995 and Heresco-Levy 1999). In two double blind, placebo controlled clinical studies it was shown that 0.4g/kg and 0.8g/kg glycine given orally along with their usual antipsychotic medication ameliorated negative symptoms by 15% and 30%, respectively. No changes were observed in side effects.
- 10 The effects of D-cycloserine were evaluated in several clinical trial. In one clinical trial doses from 15 to 250mg/d of D-cycloserine were assessed. The results showed that the dose of 50 mg/d reduced negative symptoms in schizophrenic patients (Goff 1995). In another double blind, placebo-controlled clinical trial it was found that 50mg/d along with their effective dose of antipsychotics gave an improvement in negative symptoms (Goff 1999).
- 15


*Glycine and the Glycine Cleavage System*

- Glycine is not only a neurotransmitter but also one of the major sources of C-1 building blocks. It is catabolized by the Glycine Cleavage System (GCS) to yield carbon dioxide, ammonia and methylene tetrahydrofolate.
- 20

The GCS consists of four enzymes:

- glycine decarboxylase, P-protein,
- hydrogen carrier protein, H-protein
- aminomethyltransferase, T-protein,
- 25 -dihydrolipoamide dehydrogenase, L-protein,

The following reaction scheme applies (Kikuchi 1980):



In vitro it is possible to substitute the H-protein with lipoic acid (Hiraya 1980).

## 5 SUMMARY OF THE INVENTION

The invention relates to inhibitors of the glycine cleavage system and their use as potential antipsychotic agents. It could be shown that, for example, valporate and cysteamine are potential inhibitors. The invention relates furthermore to a process for treating humans having psychosis, psychosis associated with an illness, schizophrenia, Alzheimers disease or other related psychotic disorders.

Therefore, it is an object of the invention to provide a process for treating a psychotic disorder in a human patient which comprises administering to said human a sufficient amount of an inhibitor, preferably valporate and / or cysteamine, of the glycine cleavage system.

In detail, the invention provides a process, wherein the psychotic disorder is schizophrenia, major depression, manic-depressive disorder, Alzheimers disease or post-traumatic stress syndrome.

20

Furthermore, the invention provides a process, wherein administering the glycine cleavage system inhibitor affects augmenting NMDA receptor-mediated neurotransmission.

Furthermore, it is an object of this invention to provide the use of inhibitors of the glycine cleavage system for the manufacture of a medicament directed to psychotic disorders like schizophrenia, major depression, manic-depressive disorder, Alzheimers disease or post-traumatic stress syndrome.

5

## DESCRIPTION OF THE INVENTION

### Distribution

In chicken GCS activity was found in liver, kidney and brain but not in heart or spleen. P-protein mRNA was found in liver, kidney and brain, T- and H-protein activity appeared additionally in kidney and heart.

10

In the rat brain H- and T-protein mRNA were found in olfactory bulb, cerebrum, hippocampus, cerebellum, brainstem and spinal cord. P-protein mRNA was abundant in olfactory bulb, cerebrum, hippocampus and cerebellum. This parallels the distribution of NMDA receptors (Kure 1997).

15

### P-Protein

The P-protein was characterized from chicken liver (1500g of liver yielded 8 mg of protein corresp. to 33.000 U). Its molecular weight is 208.000. It is a homodimer, each monomer carrying one molecule of pyridoxalphosphate (Hiraya, 1980). The monomers of the chicken and human P-protein have been cloned. Structural homology is 84. Disregarding changes Asp->Glu, Arg->Lys and Ser->Thr strucural homology is as high as 93% (Kume 1991). The homology between the chicken and the E. Coli enzyme is 53% (Kure 1997).

20

### 25 Known Inhibitors of the Glycine Cleavage System and Activity in Animal Models

Valproate (anticonvulsive drug, EMD 49461) is known to inhibit the GCS (Martin-Gallardo 1985). The Ki is 0.59mM, 2mM in liver and brain mitochondria, respectively. I.p. administration of 720 mg/kg in rats resulted in an elevation of glycine levels in blood, liver, brain and spinal cord to appr. 140% of control rats. Cysteamine (EMD 247 714) is an known GCS inhibitor (IC50 appr. 60µM, Lowry 1986). I.p. administration of 250 mg/kg Cysteamine in 8 day old rats caused an increase of glycine in the cortex to 360% of the control animals (Iwama 1997).

30

Other weak inhibitors are aminoacetonitrile and propargylamine (Benavides 1983).

For the PCP-induced hyperlocomotion model we use a test apparatus consisting  
5 of a clear plexiglas box (45 cm x 45 cm) equipped with two series of equally  
spaced infrared beam lights controlling X-Y axes and connected to a  
microcomputer. Measured automatically are the distance (way) traveled [m], and  
the time spent with locomotion or resting [sec] in intervals of 30 min over a total  
of 90 minutes following PCP administration. The known model substances for  
10 inhibition of the glycine cleavage system, valproate and cysteamine, are  
administered parenterally before the PCP challenge (PCP 5 mg/kg administered  
intraperitoneally). PCP at the indicated dose induces excessive locomotor  
behavior with an increase of about 200 - 250% measured by either locomotion  
distance or time compared to control animals. Valproate and cysteamine were  
15 used at doses from 100 to 500 mg/ kg. Both valproate and cysteamine reduce  
PCP-induced hyperlocomotion at various doses tested (see figures) indicating an  
antischizophrenic action.

Only limited data is available for the only more recently established model of  
20 PCP-induced disruption of prepulse inhibition (PPI). To our knowledge, only the  
glycine agonist R-(+)-HA-966 and the glycine transporter antagonists D-  
cycloserine have so-far investigated and demonstrated a reversal of PCP-  
induced PPI (Kretschmer and Koch, 1997; Furuya et al., 1998).

In the hyperlocomotion model with PCP or related drugs used as challenge  
25 stimulants, the efficacy of glycine itself, the glycine agonist R-(+)-3-amino-1-  
hydroxypyrrolid-2-one (R-(+)-HA-966), the partial agonist D-cycloserine or the  
glycine transporter antagonist glycyldodecylamide (GDA) have been repeatedly  
demonstrated in rodents (e.g. Toth and Lajtha, 1986; Toth et al., 1986; Singh et  
al., 1990; Kretschmer et al., 1992; Carlsson et al., 1994; Javitt et al., 1997;  
30 Nilsson et al., 1997; Javitt et al., 1999).

For the PCP-induced disruption of PPI we use a commercially available standard  
equipment (Coulbourn Instruments, USA) consisting of a sound attenuated test  
box equipped with a startle response measuring unit connected to a

- microcomputer; a white noise generator applies a constant level of back ground noise during the experiment. After a habituation period, a series of 70 combinations of prepulses (no prepulse or 8 to 6 dB above back ground noise) and pulses (90 to 126 dB) is randomly applied to the rats. The known model
- 5 substances for inhibition of the glycine cleavage system, valproate and cysteamine, are administered parenterally before the PCP challenge (PCP 1 - 5 mg/kg administered subcutaneously). In control animals, presentation of the prepulse inhibits the startle response elicited by the pulse alone. PCP at the indicated doses induces a disruption of PPI by a maximum of about 70%
- 10 compared to control animals. The doses indicated above are used for valproate and cysteamine, administered before the PCP challenge. Both valproate and cysteamine reverse PCP-induced disruption of PPI at different prepulse/pulse combinations at various doses tested indicating an antischizophrenic action.
- 15 Although the complex interaction of glycine with the neurotransmitter dopamine is not yet fully understood, the counterbalancing effects (symmetric bilateral changes) of glycine and dopamine, at least in part via GABAergic and cholinergic interneurons, in the central nervous system are well known for long (e.g. Cheramy et al., 1978; Giorgiueff et al., 1979; Leviel et al., 1979; Schmidt and
- 20 Kretschmer, 1997; Nankai et al., 1998). Dopamine antagonists are the classic antischizophrenic drugs, and conventional animal models to test for antischizophrenic drugs with a dopaminergic mechanism of action use the induction of stereotyped behaviours such as climbing behavior in mice by the application of dopamine-agonistic drugs such as apomorphine (Protais et al.,
- 25 1976; Puech et al., 1978).
- Using the climbing test in mice, we previously found that the glycine transporter inhibitor GDA and the partial glycine agonist D-cycloserine inhibited apomorphine (1.25 mg/kg administered subcutaneously)-induced climbing behavior in mice.
- 30 Therefore the model compound cysteamine at the doses indicated before are investigated in the climbing test in mice, too. Surprisingly again, cysteamine when given prior to the apomorphine challenge inhibit apomorphine-induced climbing at various doses with an ED50 value (dose which inhibits apomorphine-



induced climbing by 50%) of 500 mg/ kg further indicating an antischizophrenic action.

From these findings it is suggested to use inhibitors of the glycine cleavage  
5 system directly for the treatment of psychotic disorders like schizophrenia,  
schizoid or schizotypal personality disorders, disorders associated with psychosis  
such as major or manic depression, Alzheimers disease and post-traumatic  
stress syndroms. The inhibitors can be adminstered alone or together with usual  
antipsychotic drugs.

10

Fig. 1 depicts the effect of valporate (VAL) and cysteamine (CYS) on PCP induced  
hyperlocomotion, Upper panel: traveled distance, lower panel: locomotion time.  
Detailed description above.


## 15 LITERATURE

- Bakker and Amini, Compr. Psychiatry 2, 1961, 269.  
Benavides J., et al., Biochem. Pharmacol. 32, 1983, 287.  
Carlsson et al., J Neural Transm - Gen Sect 95, 1994, 223.  
Cheramy et al., Eur J Pharmacol 47, 1978, 141.  
D'Souza D.C. et al., CNS Drugs Rev. 1, 1995, 227.  
Freed et al., Neuropharmacology 23, 1984, 175.  
Furuya et al., Brain Res 781, 1998, 227.  
Giorguieff et al., J Physiol 75, 1979, 611.  
Gleason et al., Psychopharmacology 129, 1997, 79.  
Goff D.C. et al., Arch. Gen. Psychiatry 56, 1999, 21.  
Goff, D.C. et al., Am. J. Psychiatry. 152, 1995, 1213.  
Heresco-Levy U., Arch. Gen. Psychiatry 56, 1999, 29.  
Hiraya et al., J. Biolog. Chem. 255, 1980, 11664.  
Iwama H., et al., Biochem. Biophys. Res. Commun. 231, 1997, 793.  
Jackson et al., Pharmacol Biochem Behav 48, 465.  
Javitt et al., Biol Psychiatry 45, 1999, 668.  
Javitt et al., Neuropsychopharmacology 1997, 17, 202.  
Kikuchi Goro, et al. Biochem. Soc. Transactions, 1980, 504.


- Krebs-Thomson et al., Neuropsychopharmacology 18, 1998, 339
- Kretschmer and Koch, Psychopharmacology 130, 1997, 131.
- Kretschmer et al., J Neural Transm 87, 1992, 23.
- Krystal et al., Arch Gen Psychiatry 51, 1994, 199.
- Kume A., et al., J. Biolog. Chem. 266, 1991, 3323.
- Kure S., et al., Jpn. J. Human Genet., 42, 1997, 13.
- Lathi et al., Neuropsychopharmacology 13, 1995, 9.
- Leviel et al., Brain Res 175, 1979, 259.
- Luby et al., Am J Psychiatry 119, 1962, 61.
- Luby et al., Arch Neurol Psychiatry 81, 1959, 363.
- Malhotra et al., Neuropsychopharmacology 14, 1996, 301.
- Malhotra et al., Neuropsychopharmacology 17, 1997, 141.
- Martin-Gallardo, et al., Biochem. Pharmacol. 34, 1985, 2877.
- Nankai et al., Prog Neuropsychopharmacol Biol Psychiatry 22, 1998, 35.
- Nilsson et al., J Neural Transm 104, 1997, 1195.
- Pratais et al., Psychopharmacology 50, 1976, 1.
- Puech et al., Eur J Pharmacol 50, 1978, 291.
- Rosenbaum et al., Arch Gen Psychiatry 1, 1959, 651.
- Schmidt and Kretschmer, Neurosci Biobehav Rev 21, 1997, 381.
- Singh et al., Proc Natl Acad Sci USA 87, 1990, 347.
- Toth and Lajtha, Neurochem Res 11, 1986, 393.
- Toth et al., Res Commun Psychol Psychiatry Behav 11, 1986, 1.
- Vanover, Eur J Pharmacol 332, 1997, 115.
- Zylberman I. et al., N.Y. Acad. Sci. 757, 1995, 487.

**PATENT CLAIMS**

1. Use of an inhibitor of the glycine cleavage system for the manufacture of a medicament for the treatment of a psychotic disorder in a human patient.  
5
2. Use according to claim 1, wherein the psychotic disorder is selected from schizophrenia, major depression, manic-depressive disorder, Alzheimers disease or post-traumatic stress syndrome.
- 10 3. Use according to claim 2, wherein the inhibitor affects augmenting NMDA receptor-mediated neurotransmission.
4. Use according to claim 1 - 3, wherein the inhibitor of the glycine cleavage system is selected from valporate and cysteamine.  
15



(A)



(B)

Fig. 1

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/03456

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/19 A61K31/13 A61P25/18 A61P25/24 A61P25/28

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data, PAJ, CHEM ABS Data, MEDLINE, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SCHNEIDER L.S. ET AL: "Mechanism of action and prospects for cognitive enhancing medications" MEDICAL CLINICS OF NORTH AMERICA, vol. 78, no. 4, 1994, pages 911-934, XP000917566 page 916; table 2	1-4
X	MARK R. J. ET AL: "Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca <sup>2+</sup> deregulation, and cytoskeletal pathology" NEUROBIOLOGY OF AGING, vol. 16, 1995, pages 187-198, XP000917338 abstract	1-4
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"8" document member of the same patent family

Date of the actual completion of the international search

7 September 2000

Date of mailing of the international search report

21/09/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3018

Authorized officer

Seegert, K

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/03456

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; Database accession no. prev199699205075 XP002146798 abstract & TAKAHASHI M. ET AL: "Case report of sodium valproate treatment of aggression associated with Alzheimer's disease" BRAIN AND NERVE (TOKYO), vol. 48, 1996, pages 757-760,	1-4
X	KECK P.E. ET AL: "Anticonvulsants and antipsychotics in the treatment of bipolar disorder" JOURNAL OF CLINICAL PSYCHIATRY, vol. 59, 1998, pages 74-81, XP000917401 "Valproate" page 74 -page 75	1-4
X	DAVIS L.L. ET AL: "Valproate as an antidepressant in major depressive disorder" PSYCHOPHARMACOLOGY BULLETIN, vol. 32, 1996, pages 647-652, XP000917554 abstract	1-4
X	HOLTZER C.D. ET AL: "Valproate in the treatment of acute mania" JOURNAL OF PHARMACY TECHNOLOGY, vol. 12, 1996, pages 6-11, XP000917438 page 11, last paragraph	1-4
X	HAYES S.G. ET AL: "Long-term use of valproate in primary psychiatric disorders" JOURNAL OF CLINICAL PSYCHIATRY, vol. 50, 1989, pages 35-39, XP000917324 abstract	1-4
X	MORINIGO A. ET AL: "Treatment of resistant schizophrenia with valproate and neuroleptic drugs" HILLSIDE JOURNAL OF CLINICAL PSYCHIATRY, vol. 11, 1989, pages 199-208, XP000917396 abstract	1-4
X	WO 94 05280 A (SALIM AWS SHAKIR MUSTAFA) 17 March 1994 (1994-03-17) claims	1-4
P,X	WO 99 49860 A (ENDOWMENT RES INHUMAN BIOLOGY ;VALLEE BERT L (US); MARET WOLFGANG) 7 October 1999 (1999-10-07) claims 22-34	1-4

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/03456

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9405280	A	17-03-1994	AU	4975193 A	29-03-1994
WO 9949860	A	07-10-1999	AU	3470399 A	18-10-1999

**THIS PAGE BLANK** (USPTO)